Belnacasan: meta-analysis of COVID-19 studies

0 0.5 1 1.5+ All studies -34% 1 31 Improvement, Studies, Patients Relative Risk RCTs -34% 1 31 Early -34% 1 31 Belnacasan for COVID-19 c19early.org December 2025 Favorsbelnacasan Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Wortmann (DB RCT) -34% 1.34 [0.78-2.29] recov. time 14 (n) 17 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.29 Early treatment -34% 1.34 [0.78-2.29] 14 (n) 17 (n) 34% higher risk All studies -34% 1.34 [0.78-2.29] 14 (n) 17 (n) 34% higher risk 1 belnacasan COVID-19 study c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.29 Effect extraction pre-specified(most serious outcome) Favors belnacasan Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Wortmann (DB RCT) -34% 1.34 [0.78-2.29] recov. time 14 (n) 17 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.29 Early treatment -34% 1.34 [0.78-2.29] 14 (n) 17 (n) 34% higher risk All studies -34% 1.34 [0.78-2.29] 14 (n) 17 (n) 34% higher risk 1 belnacasan COVID-19 recovery result c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.29 Favors belnacasan Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Wortmann (DB RCT) -34% 1.34 [0.78-2.29] recov. time 14 (n) 17 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.29 Early treatment -34% 1.34 [0.78-2.29] 14 (n) 17 (n) 34% higher risk All studies -34% 1.34 [0.78-2.29] 14 (n) 17 (n) 34% higher risk 1 belnacasan COVID-19 Randomized Controlled Trial c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.29 Effect extraction pre-specified(most serious outcome) Favors belnacasan Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Wortmann (DB RCT) -34% 1.34 [0.78-2.29] recov. time 14 (n) 17 (n) Improvement, RR [CI] Treatment Control Wortmann (DB RCT) -43% 1.43 [0.99-2.06] recov. time 17 (n) 17 (n) Wortmann (DB RCT) -31% 1.31 [0.71-2.41] recov. time 15 (n) 8 (n) Belnacasan COVID-19 outcomes c19early.org December 2025 Favors belnacasan Favors control